A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Dec 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 68Ga-DOTA-GPFAPI-04, which is designed to help doctors see and identify various types of cancer more clearly. This agent targets a specific protein found in many tumors, allowing for better imaging during a procedure called positron emission tomography (PET). The aim is to improve the accuracy of detecting malignant tumors, especially in patients who may have already had a cancer diagnosis or are suspected of having a recurrence.

To be eligible for this trial, participants should be adults aged 18 or older who have a strong suspicion of having malignant tumors, based on previous biopsies. They should not have received chemotherapy or radiation therapy in the last three months and must be willing to undergo a biopsy or surgery if necessary. If you choose to participate, you can expect to undergo imaging tests and follow-up exams to monitor your health throughout the study. This research could lead to better ways to diagnose and treat cancer, so your involvement could help advance medical knowledge and patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with high clinical suspicion of malignant tumors;
• • 2. Those who have undergone endoscopic biopsy or puncture biopsy indicating malignant tumors but have not undergone surgery or chemotherapy;
• • 3. Previous history of malignant tumor surgery, suspected of recurrence or distant metastasis;
• • 4. There is a willingness for puncture biopsy or surgery, and there are no contraindications for puncture biopsy or surgery, and there are no contraindications for anesthesia;
• • 5. Sign an informed consent form and undergo a nuclear medicine examination, without any contraindications, with the ability and willingness to participate in the follow-up plan.
• Exclusion Criteria:
• • 1. Those who cannot tolerate puncture biopsy or surgical contraindications;
• • 2. Those who have undergone radiotherapy and chemotherapy in the past 3 months;
• • 3. Individuals who are allergic to multiple drugs or foods;
• • 4. Those who refuse nuclear medicine examinations;
• • 5. Those who do not agree to sign an informed consent form and are unable or willing to follow up.